Novo Nordisk and the Chinese Academy of Sciences establish research foundation

Published: 5-Mar-2007
Sustainability

Novo Nordisk and the Chinese Academy of Science (CAS) have signed an agreement that establishes a joint research foundation in China.


Novo Nordisk and the Chinese Academy of Science (CAS) have signed an agreement that establishes a joint research foundation in China.

The aim of Novo Nordisk-Chinese Academy of Science Research Foundation is to fund or co-fund activities of common interest within the fields of diabetes and biopharmaceuticals, including related disciplines and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology, endocrinology and drug delivery.

'Chinese and Danish scientists share a history of excellent collaborations which the new foundation will further strengthen,' said Professor Chen Zhu, CAS vice president and chairman of the Foundation. 'Novo Nordisk is well recognised in China for its major role in preventing and treating diabetes. We believe the collaboration will be of great benefit to both parties.'

In January 2002, Novo Nordisk established a world class r&d centre in Beijing. After five years of r&d activity in China, Novo Nordisk decided to cooperate with CAS and fund US$2m in supporting research in diabetes and biopharmaceuticals.

'This co-operation illustrates our long-term commitment to help in further developing the Chinese healthcare system,' said Dr Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. He stressed that Novo Nordisk will continue to launch new products in China and increase the company's r&d presence in the country.

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Manufacturing

Novozymes utilises wastewater to produce biogas

Read more
New shared biogas reactor produces as much electricity as seven offshore wind turbines, reduces carbon dioxide emissions and lowers energy costs

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
  3. Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
  4. Five API manufacturing trends you need to know in 2025 How technology, sustainability and innovation are redefining pharmaceutical production
  5. GEA raises guidance following strong H1 performance Revised forecast reflects improved margins, robust order intake and efficiency gains

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Novozymes utilises wastewater to produce biogas

New shared biogas reactor produces as much electricity as seven offshore wind turbines, reduces carbon dioxide emissions and lowers energy costs
Sustainability

Novo Nordisk donation aids efforts to combat neglected diseases

<p>Novo Nordisk has entered into a scientific collaboration that will benefit both Chinese pharmaceutical development and World Health Organization (WHO) efforts to combat neglected diseases.</p>
Sustainability

Novo Nordisk signs partnership agreement on CO2 reduction

<p>As part of its commitment to reducing its energy consumption and CO<s type=\"sub\">2</s> emissions, Danish healthcare company Novo Nordisk has signed a partnership agreement with Danish energy company DONG Energy.</p>
Sustainability

Al Gore visits Novo Nordisk

<p>Former US Vice President Al Gore, has visited the Novo Nordisk headquarters in Bagsvaerd outside Copenhagen to learn of the company\'s work to address the climate change challenge and to share ideas on how to put a halt to global warming.</p>
Sustainability

Novo Nordisk focuses r&d on therapeutic proteins: job losses to be expected

<p>Novo Nordisk is to focus all its r&d resources on the company\'s growing pipeline of protein-based pharmaceuticals. The company\'s r&d activities within small molecules for oral treatment of diabetes will be discontinued and existing projects divested.</p>
Sustainability

Novo Nordisk focuses r&d on therapeutic proteins: job losses to be expected

<p>Novo Nordisk is to focus all its r&d resources on the company\'s growing pipeline of protein-based pharmaceuticals. The company\'s r&d activities within small molecules for oral treatment of diabetes will be discontinued and existing projects divested.</p>
Sustainability

EASD, JDRF and Novo Nordisk join forces in diabetes research
Subscribe now